Analysis of the main application fields and therapeutic efficacy of ensidipine

As a targeted drug, Enasidenib's main application area is the treatment of acute myeloid leukemia (AML) carrying IDH2 gene mutations.

The main application area of ensidipine is the treatment of AML, especially those cases carrying IDH2 gene mutations. IDH2gene mutation is a common molecular marker in AML and has been detected in about 8%-19% of AML patients. This mutation causes abnormalities in cell metabolism, which in turn promotes the development of leukemia. Ensidipine, as an IDH2 inhibitor, can restore the normal metabolism of cells by inhibiting the activity of the mutated IDH2 enzyme, thereby interfering with the growth and division of leukemia cells.

Ensidipine can specifically inhibit the activity of mutated isocitrate dehydrogenase2 enzyme, reduce the production of abnormal metabolites, thereby preventing the growth of tumor cells. It can promote the differentiation of leukemia cells into normal mature blood cells, help reduce the number of abnormal leukemia cells and improve the patient's condition.

For AML symptoms such as anemia, bleeding, and infection that are commonly seen in patients, ensidipine may alleviate these symptoms during treatment. By controlling disease progression, ensidipine can help patients feel better physically and improve their quality of life.

Ensidipine can delay the progression of the disease and buy more survival time for patients. For patients with advanced AML, progression-free survival and overall survival may be prolonged.

Multiple clinical trial data support the therapeutic efficacy of ensidipine. For example, in a study that included 199 cases of relapsed or refractory AMLIn clinical trials of patients, the overall response rate (ORR) of ensidipine was 40.3%, of which the complete response rate (CR) was 19.3%< span>, the median progression-free survival (PFS) was 6.9 months, and the median overall survival (OS) was 9.3 months. These data indicate that ensidipine has significant efficacy in the treatment of AML patients harboring mutations in the IDH2 gene.

References:

https://medlineplus.gov/druginfo/meds/a617040.html